mitoxantrone has been researched along with Infection in 27 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 9.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| " The objective of the current study was to investigate the effects of combined fludarabine, mitoxantrone, and dexamethasone (FND) followed by interferon/dexamethasone on myelosuppression (absolute neutrophil counts), immunosuppression (CD4 and CD8 counts), and infectious complications in patients with previously untreated, Stage IV indolent lymphoma." | 7.73 | Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. ( Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A, 2005) |
| "Eighteen women with metastatic breast cancer entered a phase I-II study of high-dose mitoxantrone (MXT)." | 7.67 | High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial. ( Leiby, JM; Neidhart, JA; Unverfurth, DV, 1986) |
| "Prior studies of the combination of fludarabine, mitoxantrone and dexamethasone have yielded high response rates but are associated with a significant risk of opportunistic infections, predominantly Pneumocystis Carinii pneumonia (PCP) requiring routine prophylaxis." | 5.09 | Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders. ( Fox, RM; Grigg, AP; Seymour, JF; Szer, J, 2001) |
| "The review assessed the efficacy and tolerability of mitoxantrone in patients with neuromyelitis optica spectrum disorder (NMOSD)." | 5.01 | Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( Enriquez, CAG; Espiritu, AI; Pasco, PMD, 2019) |
| " The objective of the current study was to investigate the effects of combined fludarabine, mitoxantrone, and dexamethasone (FND) followed by interferon/dexamethasone on myelosuppression (absolute neutrophil counts), immunosuppression (CD4 and CD8 counts), and infectious complications in patients with previously untreated, Stage IV indolent lymphoma." | 3.73 | Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen. ( Ayala, A; Cabanillas, F; Feng, L; Hagemeister, FB; McLaughlin, P; Rodriguez, MA; Romaguera, J; Smith, TL; Tsimberidou, AM; Younes, A, 2005) |
| "Eighteen women with metastatic breast cancer entered a phase I-II study of high-dose mitoxantrone (MXT)." | 3.67 | High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial. ( Leiby, JM; Neidhart, JA; Unverfurth, DV, 1986) |
| "A total of 157 infections occurred in 61 patients (60." | 2.82 | Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004. ( Bochennek, K; Creutzig, U; Gilfert, J; Hassler, A; Lehrnbecher, T; Perner, C; Reinhardt, D; Schöning, S, 2016) |
| "In this prospective randomized trial, we compared the efficacy and toxicity of cladribine (2-CdA) alone to 2-CdA combined with cyclophosphamide (CC) or cyclophosphamide and mitoxantrone (CMC) in untreated progressive chronic lymphocytic leukemia (CLL)." | 2.72 | Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C ( Blonski, JZ; Calbecka, M; Ceglarek, B; Dmoszynska, A; Dwilewicz-Trojaczek, J; Gora-Tybor, J; Jamroziak, K; Kasznicki, M; Kloczko, J; Konopka, L; Kowal, M; Kuliczkowski, K; Robak, T; Skotnicki, AB; Stella-Holowiecka, B; Sulek, K; Tomaszewska, A; Warzocha, K; Zawilska, K, 2006) |
| " From August 1998 to December 2000 2-CdA was administered at a dosage of 0." | 2.70 | Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. ( Boguradzki, P; Błoński, JZ; Calbecka, M; Ceglarek, B; Dmoszyńska, A; Dwilewicz-Trojaczek, J; Góra-Tybor, I; Kasznicki, M; Konopka, L; Kuliczkowski, K; Moskwa-Sroka, B; Nowak, W; Robak, T; Skotnicki, AB; Stella-Hołowiecka, B; Sułek, J; Wołowiec, D, 2001) |
| "Bacterial bloodstream infections were the most frequent followed by respiratory tract infections." | 1.91 | Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. ( Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H, 2023) |
| "The median time to disease progression and median survival were 1." | 1.31 | Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. ( Blume, KG; Chao, NJ; Feiner, RH; Hu, WW; Johnston, LJ; Long, GD; Negrin, RS; Shizuru, JA; Stockerl-Goldstein, K; Wong, RM, 2000) |
| "As compared with metastatic breast cancer (MBC), high risk breast cancer showed a 2." | 1.31 | Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy. ( Barbaro, P; Console, G; Iacopino, P; Irrera, G; Martino, M; Messina, G; Morabito, F; Oliva, E; Palazzo, S; Pucci, G, 2001) |
| "Severe infections are a major problem in patients suffering from acute nonlymphocytic leukemia (ANLL) undergoing myeloablative chemotherapy." | 1.30 | Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia. ( Diehl, V; Engert, A; Hegener, K; Hübel, K; Mansmann, G; Oberhäuser, F; Schnell, R; Staib, P, 1999) |
| "Thirty-four adults with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside (ara-C) 3 g/m2 intravenously over 2 hours every 12 hours for six doses, followed by granulocyte-macrophage colony-stimulating factor (GM-CSF) 125 microgram/m2 intravenously over 4 hours daily until recovery of granulocytes above 2." | 1.28 | Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia. ( Anaissie, E; Beran, M; Estey, EH; Gutterman, J; Kantarjian, HM; Keating, MJ; O'Brien, S; Rios, MB, 1992) |
| "Myelosuppression with subsequent infections was the major toxicity of this regimen." | 1.28 | Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma. ( del Valle, F; Dörken, B; Hiddemann, W; Ho, AD; Hunstein, W; Meusers, P; Rückle, H; Schlimok, G; Schwammborn, J; Thiel, E, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (7.41) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 14 (51.85) | 29.6817 |
| 2010's | 6 (22.22) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Walti, CS | 2 |
| Halpern, AB | 2 |
| Xie, H | 2 |
| Kiem, ES | 2 |
| Chung, EL | 2 |
| Schonhoff, KG | 2 |
| Huebner, EM | 2 |
| Delaney, C | 2 |
| Liu, C | 2 |
| Pergam, SA | 2 |
| Cheng, GS | 2 |
| Kimball, LE | 2 |
| Leisenring, WM | 2 |
| Boeckh, M | 2 |
| Walter, RB | 2 |
| Hill, JA | 2 |
| Enriquez, CAG | 1 |
| Espiritu, AI | 1 |
| Pasco, PMD | 1 |
| Amadori, S | 1 |
| Suciu, S | 1 |
| Stasi, R | 1 |
| Salih, HR | 1 |
| Selleslag, D | 1 |
| Muus, P | 1 |
| De Fabritiis, P | 1 |
| Venditti, A | 1 |
| Ho, AD | 2 |
| Lübbert, M | 1 |
| Thomas, X | 2 |
| Latagliata, R | 1 |
| Halkes, CJ | 1 |
| Falzetti, F | 1 |
| Magro, D | 1 |
| Guimaraes, JE | 1 |
| Berneman, Z | 1 |
| Specchia, G | 1 |
| Karrasch, M | 1 |
| Fazi, P | 1 |
| Vignetti, M | 1 |
| Willemze, R | 1 |
| de Witte, T | 1 |
| Marie, JP | 1 |
| Hassler, A | 1 |
| Bochennek, K | 1 |
| Gilfert, J | 1 |
| Perner, C | 1 |
| Schöning, S | 1 |
| Creutzig, U | 2 |
| Reinhardt, D | 2 |
| Lehrnbecher, T | 2 |
| Guo, M | 1 |
| Hu, KX | 1 |
| Yu, CL | 1 |
| Sun, QY | 1 |
| Qiao, JH | 1 |
| Wang, DH | 1 |
| Liu, GX | 1 |
| Sun, WJ | 1 |
| Wei, L | 1 |
| Sun, XD | 1 |
| Huang, YJ | 1 |
| Qiao, JX | 1 |
| Dong, Z | 1 |
| Ai, HS | 1 |
| Larson, SM | 1 |
| Campbell, NP | 1 |
| Huo, D | 1 |
| Artz, A | 1 |
| Zhang, Y | 1 |
| Gajria, D | 1 |
| Green, M | 1 |
| Weiner, H | 1 |
| Daugherty, C | 1 |
| Odenike, O | 1 |
| Godley, LA | 1 |
| Hyjek, E | 1 |
| Gurbuxani, S | 1 |
| Thirman, M | 1 |
| Sipkins, D | 1 |
| Van Besien, K | 1 |
| Larson, RA | 1 |
| Stock, W | 1 |
| Saini, L | 1 |
| Minden, MD | 1 |
| Schuh, AC | 1 |
| Yee, KW | 1 |
| Schimmer, AD | 1 |
| Gupta, V | 1 |
| Atenafu, EG | 1 |
| Murray, C | 1 |
| Nixon, S | 1 |
| Brandwein, JM | 1 |
| Gibson, AD | 1 |
| Schmitt, B | 1 |
| Wendtner, CM | 1 |
| Bergmann, M | 1 |
| Busch, R | 1 |
| Franke, A | 1 |
| Pasold, R | 1 |
| Schlag, R | 1 |
| Hopfinger, G | 1 |
| Hiddemann, W | 2 |
| Emmerich, B | 1 |
| Hallek, M | 1 |
| Elhamri, M | 1 |
| Chelghoum, Y | 1 |
| Reman, O | 1 |
| Arnaud, P | 1 |
| Raffoux, E | 1 |
| Le, QH | 1 |
| Tavernier, E | 1 |
| Dombret, H | 1 |
| Michallet, M | 1 |
| Tsimberidou, AM | 1 |
| Younes, A | 1 |
| Romaguera, J | 1 |
| Hagemeister, FB | 1 |
| Rodriguez, MA | 1 |
| Feng, L | 1 |
| Ayala, A | 1 |
| Smith, TL | 1 |
| Cabanillas, F | 1 |
| McLaughlin, P | 1 |
| Robak, T | 2 |
| Blonski, JZ | 1 |
| Gora-Tybor, J | 1 |
| Jamroziak, K | 1 |
| Dwilewicz-Trojaczek, J | 2 |
| Tomaszewska, A | 1 |
| Konopka, L | 2 |
| Ceglarek, B | 2 |
| Dmoszynska, A | 2 |
| Kowal, M | 1 |
| Kloczko, J | 1 |
| Stella-Holowiecka, B | 1 |
| Sulek, K | 1 |
| Calbecka, M | 2 |
| Zawilska, K | 1 |
| Kuliczkowski, K | 2 |
| Skotnicki, AB | 2 |
| Warzocha, K | 1 |
| Kasznicki, M | 2 |
| Tan, RM | 1 |
| Quah, TC | 1 |
| Aung, L | 1 |
| Liang, S | 1 |
| Kirk, RC | 1 |
| Yeoh, AE | 1 |
| Tomizawa, D | 1 |
| Tabuchi, K | 1 |
| Kinoshita, A | 1 |
| Hanada, R | 1 |
| Kigasawa, H | 1 |
| Tsukimoto, I | 1 |
| Tsuchida, M | 1 |
| Zimmermann, M | 1 |
| Graf, N | 1 |
| Hermann, J | 1 |
| Niemeyer, CM | 1 |
| Reiter, A | 1 |
| Ritter, J | 1 |
| Dworzak, M | 1 |
| Stary, J | 1 |
| Advani, R | 1 |
| Saba, HI | 1 |
| Tallman, MS | 1 |
| Rowe, JM | 1 |
| Wiernik, PH | 1 |
| Ramek, J | 1 |
| Dugan, K | 1 |
| Lum, B | 1 |
| Villena, J | 1 |
| Davis, E | 1 |
| Paietta, E | 1 |
| Litchman, M | 1 |
| Sikic, BI | 1 |
| Greenberg, PL | 1 |
| Hübel, K | 1 |
| Hegener, K | 1 |
| Schnell, R | 1 |
| Mansmann, G | 1 |
| Oberhäuser, F | 1 |
| Staib, P | 1 |
| Diehl, V | 1 |
| Engert, A | 1 |
| Martino, R | 1 |
| Guardia, R | 1 |
| Altés, A | 1 |
| Sureda, A | 1 |
| Brunet, S | 1 |
| Sierra, J | 1 |
| Hu, WW | 2 |
| Negrin, RS | 2 |
| Stockerl-Goldstein, K | 1 |
| Johnston, LJ | 2 |
| Shizuru, JA | 1 |
| Wong, RM | 1 |
| Chao, NJ | 1 |
| Long, GD | 1 |
| Feiner, RH | 1 |
| Blume, KG | 2 |
| Stockerl-Goldstein, KE | 1 |
| Hoppe, RT | 1 |
| Horning, SJ | 1 |
| Błoński, JZ | 1 |
| Góra-Tybor, I | 1 |
| Boguradzki, P | 1 |
| Sułek, J | 1 |
| Wołowiec, D | 1 |
| Stella-Hołowiecka, B | 1 |
| Nowak, W | 1 |
| Moskwa-Sroka, B | 1 |
| Pérez-Gracia, JL | 1 |
| Colomer, R | 1 |
| Esteban, E | 1 |
| Barceló, R | 1 |
| Benavides, M | 1 |
| Puertas, J | 1 |
| Arcediano, A | 1 |
| Tornamira, MV | 1 |
| Valentín, V | 1 |
| Muñoz, A | 1 |
| Cortés-Funes, H | 1 |
| Hornedo, J | 1 |
| Seymour, JF | 1 |
| Grigg, AP | 1 |
| Szer, J | 1 |
| Fox, RM | 1 |
| Morabito, F | 1 |
| Irrera, G | 1 |
| Oliva, E | 1 |
| Console, G | 1 |
| Martino, M | 1 |
| Pucci, G | 1 |
| Messina, G | 1 |
| Barbaro, P | 1 |
| Palazzo, S | 1 |
| Iacopino, P | 1 |
| Kantarjian, HM | 1 |
| Estey, EH | 1 |
| O'Brien, S | 1 |
| Anaissie, E | 1 |
| Beran, M | 1 |
| Rios, MB | 1 |
| Keating, MJ | 1 |
| Gutterman, J | 1 |
| del Valle, F | 1 |
| Rückle, H | 1 |
| Schwammborn, J | 1 |
| Schlimok, G | 1 |
| Meusers, P | 1 |
| Thiel, E | 1 |
| Dörken, B | 1 |
| Hunstein, W | 1 |
| Leiby, JM | 1 |
| Unverfurth, DV | 1 |
| Neidhart, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Gemtuzumab Ozogamicin (GO) Combined With Standard Intensive Chemotherapy Versus Standard Intensive Chemotherapy Alone For Induction/Consolidation In Patients 61-75 Years Old With Previously Untreated AML: A Randomized Phase III Trial (AML-17) Of The EORTC[NCT00052299] | Phase 3 | 472 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| Multicenter Therapy-Optimization Trial AML-BFM 2004 for the Treatment of Acute Myeloid Leukemias in Children and Adolescents[NCT00111345] | Phase 2/Phase 3 | 550 participants (Actual) | Interventional | 2004-03-31 | Active, not recruiting | ||
| [NCT01674985] | Phase 1/Phase 2 | 43 participants (Actual) | Interventional | 2009-09-30 | Completed | ||
| A Pilot Study of Tc-94m Sestamibi PET MDR Imaging[NCT00082368] | Phase 2 | 12 participants (Actual) | Interventional | 2004-05-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module. (NCT00082368)
Timeframe: 69 months
| Intervention | participants (Number) |
|---|---|
| PET Imaging With Tc-94m Sestamibi | 8 |
Sestamibi is a Pgp substrate that may be a surrogate for measuring drug efflux from tumors. Significant increase in the SUV in tumor is +25% over baseline. (NCT00082368)
Timeframe: 3 days
| Intervention | % change in Tc-94m Sestamibi SUVmax (Mean) |
|---|---|
| PET Imaging With Tc-94m Sestamibi | 44 |
2 reviews available for mitoxantrone and Infection
| Article | Year |
|---|---|
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review.
Topics: Cardiomyopathies; Disease Progression; Epidemiologic Studies; Humans; Immunosuppressive Agents; Infe | 2019 |
Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Topics: Adolescent; Adult; Aged; Alemtuzumab; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodie | 2002 |
13 trials available for mitoxantrone and Infection
| Article | Year |
|---|---|
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: results of a randomized phase III trial by the EORTC and GIMEMA consortium (AML-17).
Topics: Acute Disease; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Che | 2013 |
Infectious Complications in Children With Acute Myeloid Leukemia and Down Syndrome: Analysis of the Prospective Multicenter Trial AML-BFM 2004.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Daunorubicin; D | 2016 |
Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytar | 2011 |
Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, N | 2002 |
Intensive chemotherapy with mitoxantrone administered as a single injection in patients with high-risk acute myeloid leukemia: results of the EMA 2000 trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow | 2005 |
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG C
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cyclopho | 2006 |
Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.
Topics: Acute Disease; Adolescent; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Pro | 2007 |
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; | 2006 |
Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfa | 1999 |
Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Topics: Acute Disease; Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Combined Modality | 1999 |
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cause of Death; Cladribine; Cohort Stud | 2001 |
High-dose mitoxantrone and cyclophosphamide without stem cell support in patients with high-risk and advanced breast carcinoma: a Phase II multicentric trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Female; G | 2001 |
Fludarabine and mitoxantrone: effective and well-tolerated salvage therapy in relapsed indolent lymphoproliferative disorders.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematopoietic Stem Cell Mobiliz | 2001 |
12 other studies available for mitoxantrone and Infection
| Article | Year |
|---|---|
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cy | 2023 |
High dose cytarabine and mitoxantrone: an effective induction regimen for high-risk acute myeloid leukemia (AML).
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chrom | 2012 |
Feasibility of outpatient consolidation chemotherapy in older versus younger patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Anti-Infective Agents; | 2012 |
Immunosuppression and infectious complications in patients with stage IV indolent lymphoma treated with a fludarabine, mitoxantrone, and dexamethasone regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; CD4-CD8 Ratio; De | 2005 |
Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol.
Topics: Acute Disease; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Chemical and | 2007 |
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Female; Fever | 1999 |
Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.
Topics: Adjuvants, Pharmaceutic; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; B | 2000 |
Toxicity of high-dose sequential chemotherapy and purged autologous hematopoietic cell transplantation precludes its use in refractory/recurrent non-Hodgkin's lymphoma.
Topics: Acute Kidney Injury; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Bo | 2000 |
Infectious complications in breast cancer patients undergoing peripheral blood stem cell transplantation: a single center retrospective analysis towards outpatient strategy.
Topics: Adult; Aged; Ambulatory Care; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Antineoplast | 2001 |
Intensive chemotherapy with mitoxantrone and high-dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fever; Granulocyte-Macrophage Col | 1992 |
Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation | 1989 |
High-dose mitoxantrone in metastatic breast cancer: a phase I-II trial.
Topics: Adult; Aged; Anthraquinones; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Dr | 1986 |